Skip Navigation
medication-assisted treatment for substance use disorders

Risk Management Webinar and Workshop


The webinar, Clinical Guidelines and Liability Prevention: An Overview will be a 2-1/2-hour interactive session conducted by experts in medication assisted treatment. Participants will be introduced to current liability trends and best practices for delivering methadone for opioid addiction and learn methods for reducing and preventing risks. Participants can also expect to obtain the perspective of an insurance carrier while dissecting the challenges through case studies and learning activities. An open dialogue will conclude the webinar, with questions being answered by our expert panel. Both CME and Continuing Education credits will be available, 2.5 Hours. New webinar dates to be announced in 2010.


The workshop, Clinical Guidelines and Liability Prevention, will be a full-day face-to-face training. During this workshop, attendees will learn the do’s and don’ts in current methadone practice to treat opioid addiction. Attendees will also learn how to improve patient safety through the development of comprehensive risk management strategies that incorporate best practices, treatment guidance, and affirmative risk management. These strategies also address the evidence of methadone’s use as an effective opioid addiction treatment. Both CME and Continuing Education credits will be available, 7 Hours. New workshop dates to be announced in 2010.

It is highly recommended that participants attend both the webinar and the workshop.

The 2009 workshop, which was held on October 22 in Chicago, IL, as well as the recording from the 2009 webinar event held in Pittsburgh, PA, are available for viewing at Viewing is free for both workshops and limited CE credits may be available.

Learning Objectives

Program participants will have the opportunity to ask questions and enter into a dialog with faculty and each other. Upon completion of the webinar and/or workshop, participants will have:

  • Heightened awareness of the need for increased vigilance
  • Improved ability to identify and assess risks
  • In-depth understanding of the clinical issues of induction and dosing, impairment, and cardiac factors
  • Expanded knowledge of current trends and strategies
Note to users of screen readers and other assistive technologies: Please report your problems
to us at
link to the Substance Abuse & Mental Health Services Administration division of pharmacologic therapies logo